S
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company’s pipeline include a menin inhibitor for R/R acute leukemia and a monoclonal antibody that blocks the CSF-1 receptor for chronic graft-versus-host disease. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. Review our social media community guidelines below: https://syndax.com/social-media-community-guidelines/
Investor insights
Funding rounds participated in
$350M sweet spot round size
Investor type
Public Company
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Funding rounds raised
Total raised
$350M
from investors over 1 rounds
S
Syndax Pharmaceuticals raised $350M on December 4, 2024